Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;56(2):221-228.
doi: 10.5946/ce.2022.086. Epub 2023 Mar 7.

Clinical utility of endoscopic ultrasound-guided tissue acquisition for comprehensive genomic profiling of pancreatic cancer

Nozomi Okuno  1 , Kazuo Hara  1 , Nobumasa Mizuno  1 , Shin Haba  1 , Takamichi Kuwahara  1 , Yasuhiro Kuraishi  1 , Daiki Fumihara  1 , Takafumi Yanaidani  1
Affiliations

Clinical utility of endoscopic ultrasound-guided tissue acquisition for comprehensive genomic profiling of pancreatic cancer

Nozomi Okuno et al. Clin Endosc. 2023 Mar.

Abstract

Background/aims: Endoscopic ultrasound-guided tissue acquisition (EUS-TA) is essential for the diagnosis of pancreatic cancer. The feasibility of comprehensive genomic profiling (CGP) using samples obtained by EUS-TA has been under recent discussion. This study aimed to evaluate the utility of EUS-TA for CGP in a clinical setting.

Methods: CGP was attempted in 178 samples obtained from 151 consecutive patients with pancreatic cancer at the Aichi Cancer Center between October 2019 and September 2021. We evaluated the adequacy of the samples for CGP and determined the factors associated with the adequacy of the samples obtained by EUS-TA retrospectively.

Results: The overall adequacy for CGP was 65.2% (116/178), which was significantly different among the four sampling methods (EUS-TA vs. surgical specimen vs. percutaneous biopsy vs. duodenal biopsy, 56.0% [61/109] vs. 80.4% [41/51] vs. 76.5% [13/17] vs. 100.0% [1/1], respectively; p=0.022). In a univariate analysis, needle gauge/type was associated with adequacy (22 G fine-needle aspiration vs. 22 G fine-needle biopsy [FNB] vs. 19 G-FNB, 33.3% (5/15) vs. 53.5% (23/43) vs. 72.5% (29/40); p=0.022). The sample adequacy of 19 G-FNB for CGP was 72.5% (29/40), and there was no significant difference between 19 G-FNB and surgical specimens (p=0.375).

Conclusion: To obtain adequate samples for CGP with EUS-TA, 19 G-FNB was shown to be the best in clinical practice. However, 19 G-FNB was not still sufficient, so further efforts are required to improve adequacy for CGP.

Keywords: Endoscopic ultrasound-guided fine needle aspiration; Genome; Pancreatic neoplasms.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

Dr. Mizuno reports the following grants, none of which are connected to the submitted work: from Taiho Pharmaceutical, during the conduct of the study; grants and personal fees from Novartis; personal fees from AstraZeneca; grants from NanoCarrier; grants and personal fees from MSD; grants from Dainippon Sumitomo Pharma; grants from ASLAN Pharmaceuticals; grants from Incyte; grants from Ono Pharmaceutical; personal fees from Teijin Pharma; grants and personal fees from Yakult Honsha; personal fees from Fujifilm Toyama Chemical; and grants from Seagen.

Figures

Fig. 1.
Fig. 1.
Adequate and inadequate histologic specimens obtained by EUS-FNB in the same patient (hematoxylin and eosin stain). (A) Initial inadequate sample obtained with one puncture, using a 22 G-FNB needle with suction, and processed in cell block. Although this sample was sufficient for diagnosis, it did not meet the prescreening criteria for comprehensive genomic profiling due to insufficient material. (B) Adequate sample obtained at re-EUS-TA with four punctures, using a 19 G-FNB needle without suction, placed in formalin directly and processed in biopsy. The sample could be analyzed by FoundationOne CDx (Foundation Medicine Inc.). EUS, endoscopic ultrasound; FNB, fine-needle biopsy; TA, tissue acquisition.
Fig. 2.
Fig. 2.
Mutation frequency of major driver genes for pancreatic ductal adenocarcinoma.
See this image and copyright information in PMC

Comment in

References

    1. Park DH, Lee TH, Paik WH, et al. Feasibility and safety of a novel dedicated device for one-step EUS-guided biliary drainage: a randomized trial. J Gastroenterol Hepatol. 2015;30:1461–1466. - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. - PubMed
    1. Sunami K, Ichikawa H, Kubo T, et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study. Cancer Sci. 2019;110:1480–1490. - PMC - PubMed
    1. Ebi H, Bando H. Precision oncology and the universal health coverage system in Japan. JCO Precis Oncol. 2019;3:PO.19.00291. - PMC - PubMed
    1. Haba S, Yamao K, Bhatia V, et al. Diagnostic ability and factors affecting accuracy of endoscopic ultrasound-guided fine needle aspiration for pancreatic solid lesions: Japanese large single center experience. J Gastroenterol. 2013;48:973–981. - PubMed

LinkOut - more resources